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Background: Anterior gradient 2 (AGR2) has been implicated in tumor-associated phenotypes such as cell viability,
invasion and metastasis in various human cancers. However, the tumor promoting activity of AGR2 has not yet
been determined in biliary tract cancers. Thus, we examined the expression of AGR2 and its tumor-promoting
activity in biliary tract cancer cells in this study.
Methods: Expression of AGR2 mRNA and protein was analyzed by real time RT-PCR and western blotting,
respectively. MTT assay was employed to measure cell viability and pulsed BrdU incorporation by proliferating cells
was monitored by flow cytometry. Soft agar colony formation assay and transwell invasion assay were employed to
determine anchorage-independent growth and in vitro invasion of the tumor cells, respectively. In vivo tumor
formation was examined by injection of tumor cells into immunocompromised mice subcutaneously. Statistical
analysis was performed with 2-tailed unpaired Student’s t-test for continuous data and with one-way ANOVA for
multiple group comparisons. Bonferroni tests were used for post hoc 2-sample comparisons.
Results: AGR2 mRNA was detected in SNU-245, SNU-478, and SNU-1196 cell lines, and its protein expression was
confirmed in SNU-478 and SNU-245 cell lines by western blot analysis. Knockdown of AGR2 expression with an
AGR2-specific short hairpin RNA (shRNA) in SNU-478, an ampulla of Vater cancer cell line resulted in decreased cell
viability and in decreased anchorage-independent growth by 98%. The AGR2 knockdown also increased the
sensitivity of the cells to chemotherapeutic drugs, including gemcitabine, 5-fluorouracil and cisplatin. In addition,
SNU-478 cells expressing AGR2-shRNA failed to form detectable tumor xenografts in nude mice, whereas control
cells formed tumors with an average size of 179 ± 84 mm3 in 3 weeks. Overexpression of AGR2 in SNU-869 cells
significantly increased cell viability through enhanced cell proliferation and the number of Matrigel™-invading cells
compared with AGR2-negative SNU-869 cells.
Conclusions: Our findings implicate that AGR2 expression augments tumor-associated phenotypes by increasing
proliferative and invasive capacities of the ampulla of Vater cancer cells.
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Anterior gradient 2 (AGR2, also known as hAG-2) is a
human orthologue of the Xenopus laevis cement gland-
specific gene XAG-2 that functions in specifying dor-
soanterior ectodermal fate, including formation of
cement glands and induction of forebrain fate in Xenopus
[1-3]. Human and murine AGR2 (Gob-4) expression was
first identified in estrogen receptor (ER)-positive breast
cancer cells and in goblet cells of the stomach, small in-
testine and colon, respectively [2,3]. AGR2 that belongs
to the protein disulfide isomerase (PDI) family containing
an atypical thioredoxin fold (CXXS) is essential for the
production of MUC2 protein in the intestine [4].
Specific expression of AGR2 in ER-positive breast can-
cer cells suggests that AGR2 plays a role in the patho-
genesis of ER-positive cancers [3]. Although correlation
of AGR2 expression with ER is further supported by
estrogen-dependent induction of AGR2 expression [5],
AGR2 expression is not restricted to ER-positive cancer
cells. AGR2 has been found to be expressed highly in di-
verse human cancers, including adenocarcinomas of the
esophagus [6], lung [7], pancreas [8], ovary [9] and pros-
tate [10]. AGR2 promotes metastasis of breast cancer,
hepatocellular carcinoma and head and neck squamous
carcinoma cells [11-13]. Presence of AGR2 protein in
serum and AGR2 expression in circulating tumor cells
have been reported in patients of ovarian and lung can-
cer [9,14]. Moreover, AGR2 expression is implicated in
tamoxifen resistance of breast cancer, probably due to
tamoxifen-induced AGR2 expression [15].
Tumor promoting role of AGR2 in vitro and in vivo
has been demonstrated in various contexts. Overexpres-
sion of AGR2 augments many important features of can-
cer cells including proliferation, survival, metastasis and
drug resistance (reviewed in detail by [16,17]). Con-
versely, knocking down of AGR2 expression decreases
cell growth and induces cell death in ER-positive breast
cancer cells [18]. Silencing of AGR2 expression in MPanc-
96 pancreatic cancer cell line significantly decreases tumor
growth in a xenogeneic tumor model [19]. Moreover,
AGR2-expressing NIH3T3 cells produce tumors in nude
mice [20]. These results clearly manifest the functionality
of AGR2 in tumorigenesis and tumor progression.
Cancers of the biliary tract are anatomically heteroge-
neous diseases arising at the bile duct (intrahepatic and
extrahepatic cholangiocarcinomas including Klatskin
tumor), gall bladder and ampulla of Vater [21]. Because
of the nonspecific symptoms of the disease and aggres-
sive nature of the tumor, biliary tract cancers are often
diagnosed at advanced stages and, thus highly lethal.
Although incidence, gender bias and cure rates vary
depending on primary tumor sites, overall 5-year sur-
vival rate is 5 ~ 10%, and 25 ~ 30% with curative surgery
[22]. Despite that AGR2 is implicated in tumorigenesisand tumor progression of various cancers, AGR2 expres-
sion and its tumor-promoting role in biliary tract can-
cers have not yet been studied in detail. AGR2 is
reported to be expressed in normal tissues of the biliary
tract and the expression pattern is conserved in biliary
tract cancer [23]. However, the expression and tumor-
promoting function of AGR2 in biliary tract cancer cells
have not been investigated to date. Thus, this study
aimed to analyze the expression and functional role of
AGR2 in development and maintenance of tumor phe-
notypes of biliary tract cancer cells. To this end, we de-
termined AGR2 expression in six biliary tract cancer cell
lines. In addition, tumor-promoting activity of AGR2
was examined by knockdown of AGR2 expression with
shRNA and its overexpression in AGR2-positive SNU-
478 and AGR2-negative SNU-869 ampulla of Vater
cancer cell lines, respectively.
Methods
Biliary tract cancer cell lines
Six human biliary tract cancer cell lines (SNU-245, SNU-
308, SNU-478, SNU-869, SNU-1079 and SNU-1196) and
MCF-7 breast cancer cells were procured from the Korea
Cell Line Bank (Seoul, Korea) [24]. The seven carcinoma
cell lines were cultured in RPMI-1640 medium supple-
mented with 10% fetal bovine serum, 100 U/mL penicillin,
and 100 μg/mL streptomycin in a humidified incubator
at 37°C in an atmosphere of 5% CO2. The cell lines were
subcultured by splitting at 1:8 ratios twice weekly.
Cell viability and BrdU incorporation assays
Cell viability and drug sensitivity were examined by the
MTT assay. The biliary tract cancer cells were plated in
a 96-well plate at 4000 cells/well for SNU-869 or 2000
cells/well for SNU-478 to compensate for the different
growth rates of the individual cell lines. Both SNU-478
and SNU-869 cells were plated at 8000 cells/well in a
96-well plate for drug sensitivity test. MTT solution (0.5
mg/mL, Sigma-Aldrich, St. Louis, MO, USA) was added
to each well at 72 h after plating for growth analysis and
after drug treatment for drug sensitivity test, and MTT
formazan was dissolved with lysis buffer as described by
Huynh et al. [25]. MTT conversion was measured by ab-
sorbance at 570 nm with a reference absorbance at 650
nm using a microplate spectrophotometer (Multiskan
GO, Thermo Scientific, Rockford, IL, USA).
Cell proliferation was analyzed by BrdU incorporation
assay as described in Verma et al. [26] with minor modi-
fication. SNU-869 stable transfectants were plated at 3 ×
105 cells in a 10-cm culture plates. The cells were grown
for four days and pulsed with 20 μM BrdU for 30 min.
Harvested cells by trypsinization were washed with PBS
containing 1% FBS twice and fixed in 70% ethanol for
one hour at -20°C. After washing with PBS, the fixed
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one hour at room temperature and then washed with
PBS three times. The cells were divided into two aliquots
and treated with FITC-α-BrdU (BD Biosciences, San
Jose, CA, USA) or FITC-mouse IgG1 κ isotype control
(eBioscience, San Diego, CA, USA) in dark for 45 min at
room temperature. Then, the cells were washed with
PBS twice and resuspended in 500 μL of 1.5 μg/mL 7-
AAD in PBS. Fluorescence signals of FITC-α-BrdU and
7-AAD were measured by flow cytometry using a FACS-
Calibur™ (BD Bioscience), and the data were analyzed
with CellQuest Pro software (BD Bioscience).
Quantitative real-time reverse-transcription (RT) PCR
A TRIzol reagent (JBI, Daegu, Korea) was used to extract
total RNA from the biliary tract cancer cells grown to
~70% confluence. The total RNA (5 μg) was used in re-
verse transcription reactions in 20-μL reaction mixtures
with ImProm-II™ (Promega, Madison, WI, USA), dNTPs,
and an oligo(dT) primer according to the vendor’s
protocol. Real-time PCR was carried out with the
reverse-transcribed cDNA (2 μL) using the SYBR® Green
PCR Kit (Qiagen, Hilden, Germany) in Light Cycler 2.0
(Roche, Basel, Switzerland) as directed by the manufac-
turer’s protocol. Primers used in the experiments were
the followings: AGR2 forward, 5′-ATGGAGAAAATTC
CAGTGTC-3′; AGR2 reverse, 5′-TTACAATTCAGTCT
TCAGCA-3′; glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) forward 5′-TGATGACATCAAGAAGGTGGT
GAAG-3′; and GAPDH reverse 5′-TCCTTGGAGGCC
ATGTGGGCCAT-3′. PCR was performed with the fol-
lowing cycling protocol: 1 cycle of 95°C for 10 min,
followed by 45 cycles of 95°C for 10 s, 56°C for 5 s, and
72°C for 20 s. AGR2 expression was normalized against
the expression of GAPDH.
Western blot analysis
Cells grown to 70% ~ 80% confluence were harvested by
scraping and lysed in RIPA buffer (50 mM Tris-HCl pH
7.5, 150 mM NaCl, 1% NP-40, 0.5% sodium deoxycho-
late, 1 mM EDTA, and 0.1% SDS, freshly supplemented
with 1 mM DTT and protease-inhibitor cocktails). Pro-
tein concentration was measured by the BCA method
(Thermo Scientific, Rockford, IL, USA). Protein samples
(30 μg) were resolved by 12% SDS-PAGE and electro-
blotted onto a nitrocellulose membrane. Immunode-
tection was carried out with αAGR2 antibody (rabbit
polyclonal, 1:3000 dilution, Imgenex Corp., San Diego,
CA, USA). The same blot was reprobed for β-actin to
monitor protein loading on the blot.
Establishment of stable transfectants
pLKO.1-puro-based short hairpin RNA (shRNA) expres-
sion vectors targeting AGR2 expression or a vectorcontrol (Sigma-Aldrich, St. Louis, MO, USA) was trans-
fected into SNU-478 cells using Lipofectamine® 2000
(Invitrogen, Carlsbad, CA, USA). Transfected SNU-478
cells with the shRNA control, shAGR2-1, shAGR2-2, or
shAGR2-3 were selected by treatment with puromycin
(2.5 μg/mL, Sigma-Aldrich, St. Louis, MO, USA) to es-
tablish stable AGR2-knockdown cells. To generate stable
AGR2-overexpressing and control transfectants, the
AGR2-expression vector (pcDNA3.1-AGR2) was trans-
fected into SNU-869 cells, using Lipofectamine® 2000.
AGR2 stable transfectant clones of SNU-869 were se-
lected by treatment with 0.4 mg/mL G418 (Invitrogen,
Carlsbad, CA, USA). Knockdown or overexpression of
AGR2 in the stable transfectants was verified by RT-PCR
and western blotting. The SNU-478 AGR2-knockdown
cells and SNU-869 AGR2 stable transfectants were main-
tained in medium containing puromycin (2.5 μg/mL) and
G418 (0.4 mg/mL) until further analysis, respectively.
Soft agar colony-formation assay
SNU-478 cells stably transfected with the vector control
or AGR2 shRNA were harvested by trypsinization, and
1000 cells were mixed in 0.3% top agar and plated onto
0.6% base agar in 6-cm culture dishes. Cells in the agar
were fed twice weekly and maintained for 3 weeks. Col-
onies visible in the top agar were counted directly.
Transwell invasion assay
The transwell invasion assay was performed with Bio-
coat™ Matrigel™ Invasion Chambers with 8-μm pores
(BD Biosciences) as directed by the vendor’s protocol.
AGR2-knockdown SNU-478 or AGR2-overexpressing
SNU-869 cells (5 × 104 cells/well) were resuspended in
200 μL serum-free RPMI medium and then added to the
upper chamber. Bottom chambers were filled with 1%
fetal bovine serum-RPMI, and the cells were incubated
for 24 h at 37°C in a 5% CO2 incubator. Cells present in
the coated membrane were fixed with 3.7% formalde-
hyde in PBS, permeabilized with 100% methanol for 20
min, and stained with 1% crystal violet for 1 h. The
membrane was detached, wiped with a cotton swab, and
examined under the microscope at 100 × magnification
(Olympus, Tokyo, Japan).
Formation of tumor xenografts in athymic nude mice
AGR2-knockdown SNU-478 cells and control transfec-
tants were harvested by trypsinization, washed twice in
PBS, and resuspended to a final concentration of 1.0 × 107
cells/mL. Cell suspensions (0.1 mL) were injected into the
subcutaneous tissue of the back of 3 mice (6-wk-old male
athymic BALB/c-Slc-nu/nu) per test group. The resultant
tumors were measured with calipers and the volume was
calculated with the formula, length × width × depth/2
[27]. Animals were sacrificed after observation for 21
Figure 1 AGR2 expression in cancer cell lines of the biliary
tract. A. AGR2 mRNA levels in six biliary tract cancer cell lines were
measured by real-time RT-PCR. The AGR2 transcript levels were
normalized against those of the GAPDH. Results shown are means ±
standard deviations of (1/2)CT of target - CT of GAPDH of three
experiments. B. AGR2 protein expression was detected by western
blot analysis with β-actin as a loading control. The result shown is a
representative of three experiments. Abbreviations: CBD, common
bile duct; GB, gall bladder; AoV, ampulla of Vater; IHD, intrahepatic
duct; HDB, hepatic duct bifurcation; WD, well differentiated; MD,
moderately differentiated; PD, poorly differentiated [24].
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ments were approved by the Institutional Animal Use
and Care Committee of the Korea Research Institute of
Bioscience and Biotechnology (KRIBB) and were per-
formed in accordance with the Guide for the Care and
Use of Laboratory Animals published by the US National
Institutes of Health (NIH Publication No. 85-23, revised
1996).
Statistical analysis
Statistical analysis of quantitative data was performed
with 2-tailed unpaired Student’s t-tests (for continuous
data) and with the 2-tailed Fisher’s exact test (for categorical
data). Multiple group comparisons were assessed by
one-way ANOVA. Bonferroni tests were used for post
hoc 2-sample comparisons.
Results
AGR2 is differentially expressed in biliary tract cancer cell
lines
The expression of AGR2 was examined at the levels of
mRNA and protein by real time RT-PCR and western
blot analysis, respectively, in the six human biliary tract
cancer cell lines that were established from adenocarcin-
omas of distinct differentiation status and anatomical lo-
cations [24]. Relative levels of AGR2 mRNA decreased in
the cell lines in the following order: SNU-478, -245,
-1196, -308, -869, and -1079 (Figure 1A). Expression of
the AGR2 protein was confirmed in the SNU-478 and
-245 cells (Figure 1B). AGR2 expression level in SNU-
245 was comparable to that in MCF-7 cells (Figure 1B).
The AGR2 expression pattern in the biliary tract cancer
cell lines did not appear to correlate with location or dif-
ferentiation status of the original cancer tissue directly.
Reversion of tumor phenotypes by knockdown of AGR2
expression
The SNU-478 cell line consists of poorly differentiated
cells that were established from an adenocarcinoma at
the ampulla of Vater [24]. SNU-478 exhibited the high-
est level of AGR2 expression and the fastest growth
among the six biliary tract cancer cells. Therefore, we
used the SNU-478 cells to investigate the tumor promot-
ing role of AGR2 by silencing its expression with an
AGR2 shRNA. Compared with AGR2 expression in cells
transfected with the vector control (SNU-478:VEC), the
expression of AGR2 mRNA was knocked down by 79% ~
98% in three stable transfectants expressing AGR2
shRNA (SNU-478:KD1 ~ 3; Figure 2A). AGR2 protein
was undetectable in the AGR2 shRNA-expressing cells by
western blot analysis (Figure 2B). The effect of AGR2 ex-
pression on cell viability was assessed with the SNU-478:
KD cells by the MTT assay. Knockdown of AGR2 expres-
sion significantly decreased the viability of the SNU-478:KD2 and KD3 cells, and moderately decreased the viabil-
ity of the SNU-478:KD1 cells (Figure 2C). Overall, knock-
down of AGR2 expression in the SNU-478:KD cells
decreased cell viability by 7 ~ 13% compared to the SNU-
478:VEC, suggesting an association of AGR2 expression
with cell growth and survival.
Colony-forming ability in soft agar was compared
among the SNU-478:VEC and SNU-478:KD cells to de-
termine the effect of AGR2 expression on anchorage-
independent growth. Knockdown of AGR2 expression
dramatically decreased the number of colonies on soft
agar. SNU-478:KD cells formed 98% fewer colonies in
soft agar than the SNU-478:VEC cells (Figure 2D).
AGR2 is known to enhance invasiveness of tumor cells
[9,19,20]. Therefore, modulation of invasiveness by
AGR2 was examined by transwell invasion assays with
the SNU-478:VEC and SNU-478:KD cells. Unlike the re-
sults of the soft agar colony-forming assay, the AGR2
knockdown resulted in mixed responses among the KD
clones and did not significantly inhibit invasion of the
tumor cells. However, SNU-478:KD cells tended to be
less invasive than SNU-478:VEC cells (Figure 2E), sug-
gesting a weak association of AGR2 expression with
tumor invasiveness. On the basis of the above results of
Figure 2 Alterations of tumor-associated phenotypes in AGR2-silenced SNU-478 cells. A. Expression of AGR2 mRNA in SNU-478:KD (AGR2
knockdown) clones was compared with that in SNU-478:VEC (vector control) by real-time RT-PCR. The AGR2 transcript level was normalized against that
of GAPDH. Results shown are means ± standard deviations of (1/2)CT of target - CT of GAPDH of three experiments. B. AGR2 protein expression in SNU-478:
VEC and SNU-478:KDs was detected by western blot analysis with β-actin as a loading control. The result shown is a representative of three
experiments. C. Viability of SNU-478:VEC and SNU-478:KDs was measured by the MTT assay. Results shown are means ± standard deviations of three
experiments (ANOVA P = 0.010; post hoc analysis by Bonferroni testing: KD2 vs. VEC, P = 0.016). D. Anchorage-independent growth was examined by
colony formation assay in soft agar. The number of colonies formed in the soft agar assay with SNU-478:VEC and SNU-478:KDs. Results shown are
means ± standard deviations of three experiments (ANOVA P = 0.000; post hoc analysis by Bonferroni testing: KD1-3 vs. VEC, P = 0.000). E. The number
of invading cells in the transwell invasion assay with SNU-478:VEC and SNU-478:KDs. Results shown are means ± standard deviations of three
experiments (ANOVA P = 0.042). F. Drug sensitivity of SNU-478:VEC and SNU-478:KDs was measured by the MTT assay. Cells plated in a 96-well plate
were treated with gemcitabine (20 μg/mL), cisplatin (0.5 μg/mL), or 5-FU (50 μg/mL), and the MTT assay was carried out on day three of the treatments.
(ANOVA P = 0.000 for gemcitabine; ANOVA P = 0.048 for cisplatin; ANOVA P = 0.001 for 5-FU).
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assays, AGR2 expression is assumed to augment tumor-
specific phenotypes including anchorage-independent
growth and invasiveness.
Knockdown of AGR2 expression has been shown to
increase the sensitivity of MPanc-96 cells to gemcitabine
[19]. Therefore, MTT assay was used to investigate
whether knockdown of AGR2 expression altered drug
sensitivities of SNU-478 cells (Figure 2F). Knockdown of
AGR2 rendered the SNU-478:KD cells significantly moresensitive to gemcitabine, cisplatin and 5-fluorouracil
(FU) than the SNU-478:VEC cells. SNU-478:KD cells
were ~57% more sensitive to gemcitabine, ~24% to cis-
platin, and ~43% to 5-FU than the SNU-478:VEC cells.
AGR2 knockdown affected sensitivity of the cells to
gemcitabine more severely than those to cisplatin and
5-FU.
Finally, we examined the effect of AGR2 expression on
in vivo tumor formation by injecting an equal number of
SNU-478:VEC and SNU-478:KD2 cells into BALB/c-Slc-
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fested all of the phenotypic characteristics resulted from
knockdown of AGR2 expression in SNU-478:KD cells
representatively (Figure 2A). Tumor xenografts were
formed after injection with the SNU-478:VEC cells, but
no palpable tumor mass was detected in mice injected
with the SNU-478:KD2 cells (Figure 3A,B insert). The
tumor mass of the SNU-478:VEC cells continued to in-
crease until 21 days post injection to 179.00 ± 84.06
mm3, whereas the tumor mass of the SNU-478:KD2 cells
briefly increased in the first week and, then, regressed
over time (Figure 3B). The observed failure of the SNU-
478:KD2 cells to form tumor clearly supports a tumor-
promoting role of AGR2 expression in vivo.
Augmentation of tumor phenotypes by overexpression of
AGR2
Knockdown of AGR2 expression in SNU-478 cells sup-
pressed certain tumor phenotypes, including growth,
anchorage-independent growth, and in vivo tumor xeno-
graft formation. To further confirm the AGR2 effects onFigure 3 The effect of the AGR2 knockdown on in vivo tumor
formation of SNU-478 cells. In vivo tumor formation was examined
by subcutaneously injecting SNU-478:VEC or SNU-478:KD2 cells into
athymic nude mice. A. Mice were injected with SNU-478:VEC
(left side) or SNU-478:KD2 (right side) cells and nursed for 21 days.
B. Increase in tumor size measured after a week post injection as
volume (mm3) every two days for 21 days. Results shown are
means ± standard deviations of three mice (Student’s t-test,
P = 0.021). B-insert. Resected tumors formed by SNU-478:VEC after
21 days post injection.the development of these tumor phenotypes, AGR2 was
overexpressed in the SNU-869 cell line, another ampulla
of Vater cancer cell line which shows negligible expres-
sion of AGR2. In contrast to SNU-478, SNU-869 is a
well-differentiated adenocarcinoma cell line [24]. Three
stable AGR2-overexpressing transfectants (SNU-869:
AGR2-1 ~ 3) and one AGR2-negative clone (SNU-869:
AGR2-N) were established and expression of AGR2 in
the transfectants was confirmed at the levels of mRNA
and protein by RT-PCR and western blotting, respect-
ively (Figure 4A and B).
The viability of the SNU-869 stable transfectants mea-
sured by the MTT assay showed that AGR2 expression
significantly increased cell viability (Figure 4C). The viabil-
ity of the SNU-869:AGR2 clones was on average ~42%
higher than that of SNU-869:AGR2-N, providing further
support for the growth- and/or survival-enhancing
effects of AGR2. In order to determine the mechanism of
the elevated cell viability in the SNU-869:AGR2 cells, cell
proliferation rate was measured by pulsed BrdU incorp-
oration assay. Percentage of BrdU-positive cells was 8.4%
higher on average in 7-AAD-positive SNU-869:AGR2
cells compared to 7-AAD-positive SNU-869:AGR2-N
(P = 0.053, Figure 4D). Moreover, percent BrdU-positive
cells normalized against SSC were 8.8% higher on average
in SNU-869:AGR2 cells compared to SNU-869:AGR2-N
(21 ± 2.4 in AGR2-N vs. 30.0 ± 5.9, 26.9 ± 4.1 and 32.4 ±
6.3 in AGR2-1 ~ 3, respectively, P =0.036). These results
suggest that the enhanced proliferation rate could
account for the viability increase of the SNU-869:AGR2
cells.
The effect of AGR2 on the invasiveness of tumor cells
was examined by the transwell migration assay with the
SNU-869:AGR2 and SNU-869:AGR2-N cells (Figure 4E).
Invasion of the tumor cells was significantly increased
by AGR2 overexpression in the SNU-869:AGR2 cells.
The number of invading cells was increased on average
by about 3-fold in SNU-869:AGR2 over SNU-869:
AGR2-N. Thus, AGR2 overexpression seems to enhance
the viability and invasiveness of the SNU-869 cells. How-
ever, in contrast to the results with the SNU-478:KD
cells, overexpression of AGR2 in SNU-869 cells did not
result in prominent changes in anchorage-independent
growth and drug sensitivities (data not shown).
Discussion
AGR2 enhances several tumor-specific phenotypes includ-
ing cell proliferation, survival, anchorage-independent
growth, invasiveness through Matrigel™ and metastasis
[13,19,20]. Drug resistance of cancer cells against gemci-
tabine and tamoxifen is also affected by AGR2 expression
[19,28,29]. Knockdown of AGR2 expression in SNU-478
cells lowered the viability of the cells, increased their
sensitivity to chemotherapeutic drugs, and decreased
Figure 4 Alterations of tumor-associated phenotypes by overexpression of AGR2 in SNU-869 cells. A. AGR2 expression in the SNU-869
stable transfectants was verified by real-time RT-PCR. The AGR2 transcript level was normalized against that of GAPDH. Results shown are
means ± standard deviations of (1/2)CT of target - CT of GAPDH of three experiments. B. AGR2 protein expression in the SNU-869 stable transfectants
was detected by western blot analysis with β-actin as a loading control. The result shown is a representative of three experiments. C. Viability of
the SNU-869 stable transfectants was measured by the MTT assay. Results shown are means ± standard deviations of three experiments (ANOVA
P = 0.008; post hoc analysis by Bonferroni testing: AGR2-2 vs. AGR2-N, P = 0.013). D. The effect of AGR2 overexpression on cell proliferation. Pulsed
BrdU incorporation into the SNU-869 stable transfectants was measured by flow cytometry. Percentage of BrdU-positive cells was shown in
mean ± standard deviation of four experiments (ANOVA P = 0.053; post hoc analysis by Bonferroni testing: AGR2-2 vs. AGR2-N, P = 0.027). Results
shown are representatives of four experiments. E. The effect of AGR2 overexpression on tumor cell invasion of SNU-869 cells. The numbers of
invading cells in the transwell invasion assay were determined for SNU-869 stable transfectants. Results shown are means ± standard deviations
of three experiments (ANOVA P = 0.003; post hoc analysis by Bonferroni testing: AGR2-2 vs. AGR2-N, P = 0.026).
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AGR2 expression in SNU-869 cells significantly increased
cell viability and Matrigel™ invasiveness. AGR2 expres-
sion in SNU-869 enhanced cell proliferation rate that
should result in the increased cell viability measured by
the MTT assay as in normal mammary epithelial cells and
in various cancer cells [9,13,18,26]. Thus, AGR2 expression
is supposed to augment the tumorigenic potential of the
biliary tract cancer cells by increasing the viability, invasive-
ness and anchorage-independent growth of these cells as
was observed in other cancer cells [13,19].
AGR2 is also positively correlated with in vivo tumor-
forming ability in athymic nude mice and metastasis of
tumor cells. Knockdown of AGR2 expression in MPanc-96 pancreatic cancer cell line and in SEG-1 esophageal
adenocarcinoma cell line results in significant reduction
of in vivo tumor growth [19,20]. In addition, rat mammary
tumor cells overexpressing AGR2 showed increased meta-
static potential when injected orthotopically in syngeneic
rats [11]. No detectable tumor xenograft was formed in
nude mice injected with AGR2-silenced SNU-478 cells,
whereas AGR2-expressing SNU-478 cells formed palpable
tumors. Loss of in vivo tumorigenic potential of SNU-478
cells after AGR2 knockdown suggests that AGR2 expres-
sion is required to establish and to maintain stable tumor
xenograft of the biliary tract cancer cells.
However, both knockdown of AGR2 expression in
SNU-478 and AGR2 overexpression in SNU-869 were
Kim et al. BMC Cancer 2014, 14:804 Page 8 of 10
http://www.biomedcentral.com/1471-2407/14/804only partially effective in altering certain cancer pheno-
types and affected distinct properties in each cell line.
Knockdown of AGR2 in SNU-478 cells had only mar-
ginal effects in the Matrigel™ invasion assay. In addition,
AGR2 expression in SNU-869 cells did not increase
anchorage-independent growth, drug resistance and for-
mation of tumor xenograft significantly. Despite that
both SNU-478 and SNU-869 cells were originated from
tumors of the ampulla of Vater, they were different from
each other in their AGR2 expression, differentiation sta-
tus, growth kinetics and drug responses [24]. Therefore,
the phenotypic difference between SNU-478 and SNU-
869 might account for the distinct responses to modula-
tion of AGR2 expression in the two cells. Otherwise, par-
tial reversion of the cancer phenotypes by modulation of
AGR2 expression could also implicate that AGR2 by it-
self is insufficient and requires presence of additional cell
specific component(s) to cause the necessary change.
The mechanism underlying the AGR2-associated
tumor promotion has been being investigated recently.
AGR2 silences UV-induced p53 transactivation activity
by attenuating p53 phosphorylation in H1299 cells [6].
In addition, overexpression of AGR2 upregulates genes
that are involved in cell proliferation, invasion and
angiogenesis [9]. Meanwhile, knockdown of AGR2
expression results in downregulation of cyclin D1, survi-
vin, and c-Myc [18]. Moreover, AGR2 expression is sup-
pressed by SMAD4 that is a tumor suppressor of
pancreatic ductal adenocarcinoma [30]. In addition, in-
duction of AGR2 expression by tamoxifen through AKT
or Src has been implicated in tamoxifen resistance of
breast cancer cells [31]. Both AGR2-mediated inhibition
of p53 tumor suppressor activity and AGR2-associated
expression of genes that regulate cell growth and sur-
vival may directly contribute to the tumor-promoting ac-
tivity of AGR2 through augmented cell proliferation and
survival. Meanwhile, increased invasiveness and metasta-
sis associated with AGR2 expression might be the result
of regulation of cathepsins B and D expression, en-
hanced angiogenesis and modulation of extracellular
matrix by AGR2 [30,32,33]. It is plausible that changes
in the AGR2-associated gene expression regulate the
tumor phenotypes of the biliary cancer cells including
viability, anchorage-independent growth and invasive-
ness. Therefore, initial clues to determine the mechan-
ism of the AGR2-enhanced tumorigenic potential and
drug resistance of the biliary cancer cells can be ob-
tained by detailed investigation in the AGR2-associated
alterations in gene expression pattern.
Although AGR2 expression was found to enhance
tumor-associated phenotypes of the biliary tract cancer
cells, caution should be taken to correlate these results
with tumor progression and prognosis of biliary tract can-
cer patients directly. An immunohistochemical analysis ofAGR2 expression pattern demonstrated that AGR2 ex-
pression in the biliary tract is not tumor specific, but is
associated with anatomical location and mucin-secreting
phenotype [23]. An independent study on AGR2 expres-
sion in tissue specimens of biliary tract cancer patients
revealed that AGR2 expression was higher in tumors of
lower stage and advanced differentiation [34]. Such
discrepancy between in vitro tumor-promoting role of
AGR2 and tumor progression in patients has also been
reported in pancreatic cancer studies. Whereas knock-
down of AGR2 in pancreatic cancer cells decreases cell
proliferation and invasion, and increases drug sensitivity
[19], AGR2 expression in tissue samples of pancreatic
cancer patients is positively correlated with differenti-
ation status of the cancer [35]. In this case, aberrant
AGR2 expression in poorly differentiated cancer is corre-
lated with worse prognosis of the patients, suggesting
that tumor promoting role of AGR2 is specific to tumor
type and stage [35]. Lack of correlation between in vitro
tumor-promoting activity of AGR2 and pathologic find-
ings in biliary tract cancer patients is an issue to be re-
solved. It is conceivable that uncoupling of AGR2
expression from tumor progression of biliary tract cancers
can be ascribed to peculiarity of biliary tract cancers in-
cluding cancer microenvironment. Since AGR2 mani-
fested tumor promoting activity in ampulla of Vater
cancer cells, pathologic relevance of AGR2 expression in
carcinogenesis of the ampulla of Vater should also be in-
vestigated in detail. An orthotopic biliary tract cancer
model in which AGR2 expression can be modulated spe-
cifically in the biliary tract might be required to provide
more definitive evidences on in vivo tumor-promoting
function of AGR2 in biliary tract cancers.
Conclusions
By analyzing AGR2 expression and its tumor-promoting
role in vitro and in vivo, we have provided evidences for
tumor-promoting activities of AGR2 in ampulla of Vater
cancer cells for the first time. AGR2 is thought to pro-
mote tumor formation by augmenting cell viability,
anchorage-independent growth, and invasive properties
of the biliary tract cancer cells. The mechanisms under-
lying the AGR2-associated tumor promotion in the bil-
iary tract cancer cells and the observed discrepancy in
the tumor promoting potential of AGR2 in different cells
remain to be elucidated in future studies in which AGR2
knockdown SNU-478 or AGR2 overexpressing SNU-869
could be utilized as a valuable model system.
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